Small molecule · Inhibitor of ROS1 · developed by Nuvation
Taletrectinib is an orally available kinase inhibitor that binds and inhibits ROS1, including ROS1 resistance mutations, and also inhibits TRKA, TRKB and TRKC. It blocks ROS1- and TRK-driven signaling that promotes unconstrained cell proliferation in tumor cells. It is studied in non-small cell lung cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 23, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06564324 | Phase 3 | Non Small Cell Lung Cancer | Recruiting | NUVB |
| NCT04395677 | Phase 2 | Non Small Cell Lung Cancer | Active not recruiting | NUVB |
| NCT07742384 | Phase 1 | Healthy Adult Participants | Not yet recruiting | NUVB |
| NCT05609929 | Phase 1 | Pharmacokinetic Study | Completed | NUVB |
| NCT05357820 | Phase 1 | Solid Tumor | Completed | NUVB |
| NCT05357911 | Phase 1 | Solid Tumor | Completed | NUVB |
| NCT02279433 | Phase 1 | Solid Tumors | Completed | NUVB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Adult ParticipantsNon Small Cell Lung CancerPharmacokinetic StudySolid Tumor
Updated Oct 11, 2026. Something wrong or missing? Report it on the NUVB page.
See NUVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NUVB catalysts and pipeline →